Your browser doesn't support javascript.
loading
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy.
Socié, Gérard; Barba, Pere; Barlev, Arie; Sanz, Jaime; García-Cadenas, Irene; Chevallier, Patrice; Fagioli, Franca; Guzman-Becerra, Norma; Kumar, Deepali; Ljungman, Per; Pigneux, Arnaud; Sadetsky, Natalia; Yáñez San Segundo, Lucrecia; Shadman, Mazyar; Storek, Jan; Thirumalai, Dhanalakshmi; Xing, Baodong; Mohty, Mohamad.
Afiliación
  • Socié G; Hôpital Saint-Louis, Paris, France.
  • Barba P; Hospital Universitari Vall Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Barlev A; Atara Biotherapeutics, Thousand Oaks, CA, USA. abarlev@atarabio.com.
  • Sanz J; Hospital Universitari I Politècnic La Fe, Valencia, Spain.
  • García-Cadenas I; Hematology Division, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
  • Chevallier P; CHU Hotel Dieu, Nantes, France.
  • Fagioli F; Regina Margherita Children's Hospital, AOU Città della Salute e della Scienza, Turin, Italy.
  • Guzman-Becerra N; University of Turin, Turin, Italy.
  • Kumar D; Atara Biotherapeutics, Thousand Oaks, CA, USA.
  • Ljungman P; Transplant Infectious Diseases and Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada.
  • Pigneux A; Karolinska Institutet Huddinge, Stockholm, Sweden.
  • Sadetsky N; Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
  • Yáñez San Segundo L; CHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France.
  • Shadman M; Atara Biotherapeutics, Thousand Oaks, CA, USA.
  • Storek J; Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain.
  • Thirumalai D; University of Washington, Seattle, WA, USA.
  • Xing B; Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Mohty M; University of Calgary, Calgary, AB, Canada.
Bone Marrow Transplant ; 59(1): 52-58, 2024 01.
Article en En | MEDLINE | ID: mdl-37865719
Epstein-Barr virus-positive (EBV+) post-transplant lymphoproliferative disease (PTLD) is an ultra-rare and aggressive condition that may occur following allogeneic hematopoietic cell transplant (HCT) due to immunosuppression. Approximately half of EBV+ PTLD cases are relapsed or refractory (R/R) to initial rituximab-containing therapy. There are limited treatment options and no standard of care for patients with R/R EBV+ PTLD, and little is known about their treatment history and outcomes. We performed a multinational, multicenter, retrospective chart review of patients with R/R EBV+ PTLD following HCT to describe patients' demographic and disease characteristics, treatment history, and overall survival (OS) from rituximab failure. Among 81 patients who received initial treatment with rituximab as monotherapy (84.0%) or in combination with chemotherapy (16.0%), median time from HCT to PTLD diagnosis was 3.0 months and median OS was 0.7 months. Thirty-six patients received a subsequent line of treatment. The most frequent causes of death were PTLD (56.8%), graft-versus-host disease (13.5%) and treatment-related mortality (10.8%). In multivariate analysis, early PTLD onset and lack of response to initial treatment were associated with mortality. This real-world study demonstrates that the prognosis of patients with R/R EBV+ PTLD following HCT remains poor, highlighting the urgent unmet medical need in this population.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Infecciones por Virus de Epstein-Barr / Trastornos Linfoproliferativos Límite: Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Infecciones por Virus de Epstein-Barr / Trastornos Linfoproliferativos Límite: Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido